Inherited mutations of the BRCA1 and BRCA2 genes confer women with a profound predisposition to breast and ovarian cancer. Studies by many groups have characterized germline alterations in >400 independent breast and ovarian cancer families. More than 90% of reported mutations result in truncated proteins due to frameshift, nonsense, or splicing errors. For rapid localization of mutations prior to DNA sequencing, a series of protein truncation and dideoxy-fingerprinting have been developed. As reported with BRCA1, somatic mutations of BRCA2 in sporadic breast and ovarian cancers are extremely rare. In order to identify functional domains of BRCA1 and BRCA2 through evolutionary conservation, we have characterized the mouse and rat homologues of these genes. In addition to the RING finger motif of BRCA1, nuclear localization signals and a carboxy terminal domain with homology to a P53-binding protein are highly conserved. Likewise, a large internal repeat of unknown function has been highly conserved in BRCA2. In contrast, the granin motif, which led to the proposal that these proteins may be involved in a regulated secretory pathway, is poorly conserved in rodents. As an initial step towards development of mouse models for BRCA1 and BRCA2 defects, we have created several targeting vectors for homologous recombination. Repeated attempts to disrupt the RING finger domain of BRCA1 have been unsuccessful. Current efforts are focused on the identification embryonic stem cells with the desired BRCA2 targeting event that will delete portions exon 10 and 11-+.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES023000-09
Application #
2342862
Study Section
Special Emphasis Panel (LMC)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1996
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
McAllister, Kimberly A; Bennett, L Michelle; Houle, Chris D et al. (2002) Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res 62:990-4
Wagner, K U; McAllister, K; Ward, T et al. (2001) Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10:545-53
Hohenstein, P; Kielman, M F; Breukel, C et al. (2001) A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene 20:2544-50
Bennett, L M; McAllister, K A; Ward, T et al. (2001) Mammary tumor induction and premature ovarian failure in ApcMin mice are not enhanced by Brca2 deficiency. Toxicol Pathol 29:117-25
Bennett, L M; McAllister, K A; Malphurs, J et al. (2000) Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res 60:3461-9
Lubet, R A; Zhang, Z; Wiseman, R W et al. (2000) Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res 26:581-93
Zhang, Z; Liu, Q; Lantry, L E et al. (2000) A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res 60:901-7
Bennett, L M; McAllister, K A; Blackshear, P E et al. (2000) BRCA2-null embryonic survival is prolonged on the BALB/c genetic background. Mol Carcinog 28:174-83
Blackshear, P; Mahler, J; Bennett, L M et al. (1999) Extragonadal teratocarcinoma in chimeric mice. Vet Pathol 36:457-60